The single most important risk factor for post-transplant lymphoma is a lack of previous exposure to Epstein-Barr virus (EBV).
The greatest risk is with EBV-positive donor organs being transplanted to EBV-negative recipients.
A more important risk factor for post-transplant lymphoproliferative disease (PTLD) is the dose of anti-thymocyte immunoglobulin (thyroglobulin) utilized for the treatment of rejection. PTLD has the highest incidence in small intestinal transplants in which thyroglobulin is administered to both donors (to prevent graft vs host) and recipients.
Studies indicate that seronegativity to EBV increases post-transplant lymphomas.
*eMedicine, Google Scholar, UpToDate, WheelessOnline, and DermNet are not affiliated with StatPearls. We do not control their content or advertising.
Adult Lab Normals
Pediatric Lab Normals
Cancer risk following organ transplantation: a nationwide cohort study in Sweden., Adami J,Gäbel H,Lindelöf B,Ekström K,Rydh B,Glimelius B,Ekbom A,Adami HO,Granath F,, British journal of cancer, 2003 Oct 6 [PubMed PMID: 14520450]
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study., Curtis RE,Travis LB,Rowlings PA,Socié G,Kingma DW,Banks PM,Jaffe ES,Sale GE,Horowitz MM,Witherspoon RP,Shriner DA,Weisdorf DJ,Kolb HJ,Sullivan KM,Sobocinski KA,Gale RP,Hoover RN,Fraumeni JF Jr,Deeg HJ,, Blood, 1999 Oct 1 [PubMed PMID: 10498590]
Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?, Nelson BP,Nalesnik MA,Bahler DW,Locker J,Fung JJ,Swerdlow SH,, The American journal of surgical pathology, 2000 Mar [PubMed PMID: 10716151]
Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988-97: a Canadian multi-centre experience., Allen U,Hébert D,Moore D,Dror Y,Wasfy S,, Pediatric transplantation, 2001 Jun [PubMed PMID: 11422823]
Post-transplant lymphoproliferative disorders., Singavi AK,Harrington AM,Fenske TS,, Cancer treatment and research, 2015 [PubMed PMID: 25655616]
Infection in organ transplantation: risk factors and evolving patterns of infection., Fishman JA,Issa NC,, Infectious disease clinics of North America, 2010 Jun [PubMed PMID: 20466270]
Post-transplant lymphoproliferative disorders: from treatment to early detection and prevention?, Bakker NA,van Imhoff GW,, Haematologica, 2007 Nov [PubMed PMID: 18024391]
Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders., Cen H,Williams PA,McWilliams HP,Breinig MC,Ho M,McKnight JL,, Blood, 1993 Mar 1 [PubMed PMID: 8382973]
Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States., Dharnidharka VR,Lamb KE,Gregg JA,Meier-Kriesche HU,, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2012 Apr [PubMed PMID: 22226225]
Post-Transplantation Lymphoproliferative Disorders in Adults., Dierickx D,Habermann TM,, The New England journal of medicine, 2018 Feb 8 [PubMed PMID: 29414277]
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial., Trappe R,Oertel S,Leblond V,Mollee P,Sender M,Reinke P,Neuhaus R,Lehmkuhl H,Horst HA,Salles G,Morschhauser F,Jaccard A,Lamy T,Leithäuser M,Zimmermann H,Anagnostopoulos I,Raphael M,Riess H,Choquet S,, The Lancet. Oncology, 2012 Feb [PubMed PMID: 22173060]